Vunakizumab (Anti-CTLA-8 / IL-17a)

Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.
Supplier Selleck Chemicals
Product # A2866
Sku # A2866-1mg*5
Pricing 1mg*5, $970.00
Feedback